4.6 Review

The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis

期刊

PLOS ONE
卷 17, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0268677

关键词

-

资金

  1. Philips S.p.A

向作者/读者索取更多资源

This study assesses the economic burden of obstructive sleep apnea (OSA) in the adult population in Italy, finding that its impact is highly underestimated due to low diagnosis and treatment rates. The results demonstrate that the economic burden caused by OSA is substantial, with various clinical and non-clinical conditions contributing significantly to the overall cost. These findings highlight the need for increased awareness of OSA and evidence-based policies to ensure appropriate care for patients.
Background Obstructive sleep apnea (OSA) is a risk factor for several diseases and is correlated with other non-medical consequences that increase the disease's clinical and economic burden. However, OSA's impact is highly underestimated, also due to substantial diagnosis gaps. Objective This study aims at assessing the economic burden of OSA in the adult population in Italy by performing a cost-of-illness analysis with a societal perspective. In particular, we aimed at estimating the magnitude of the burden caused by conditions for which OSA is a proven risk factor. Methods A systematic literature review on systematic reviews and meta-analyses, integrated by expert opinion, was performed to identify all clinical and non-clinical conditions significantly influenced by OSA. Using the Population Attributable Fraction methodology, a portion of their prevalence and costs was attributed to OSA. The total economic burden of OSA for the society was estimated by summing the costs of each condition influenced by the disease, the costs due to OSA's diagnosis and treatment and the economic value of quality of life lost due to OSA's undertreatment. Results Twenty-six clinical (e.g., diabetes) and non-clinical (e.g., car accidents) conditions were found to be significantly influenced by OSA, contributing to an economic burden ranging from Euro10.7 to Euro32.0 billion/year in Italy. The cost of impaired quality of life due to OSA undertreatment is between Euro2.8 and Euro9.0 billion/year. These costs are substantially higher than those currently borne to diagnose and treat OSA (Euro234 million/year). Conclusions This study demonstrates that the economic burden due to OSA is substantial, also due to low diagnosis and treatment rates. Providing reliable estimates of the economic impact of OSA at a societal level may increase awareness of the disease burden and help to guide evidence-based policies and prioritisation for healthcare, ultimately ensuring appropriate diagnostic and therapeutic pathways for patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据